General Atlantic LLC Akero Therapeutics, Inc. Transaction History
General Atlantic LLC
- $2.96 Billion
- Q1 2025
A detailed history of General Atlantic LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, General Atlantic LLC holds 5,233,989 shares of AKRO stock, worth $270 Million. This represents 7.15% of its overall portfolio holdings.
Number of Shares
5,233,989
Previous 5,233,989
-0.0%
Holding current value
$270 Million
Previous $146 Million
45.51%
% of portfolio
7.15%
Previous 5.21%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
269Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$382 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$364 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$306 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$288 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.82MShares$248 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.39B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...